FHTX

Peers: PRLD CCCC ARVN GLUE NRIX KYMR BDTX IDYA ZNTL ALXO

| Held by: VTI IWM VXF VTWO IWO IBB IWC BUSM VTWG OMFS

Index	RUT
Market Cap	119.36M
Enterprise Value	-5.12M
Income	-64.58M
Sales	36.74M
Book/sh	-1.38
Cash/sh	2.82
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	106
IPO	Oct 23, 2020

P/E	-
Forward P/E	-
PEG	-
P/S	3.25
P/B	-
P/C	0.71
P/FCF	-
EV/EBITDA	-
EV/Sales	-0.14
Quick Ratio	3.36
Current Ratio	3.36
Debt/Eq	-
LT Debt/Eq	-
Option/Short	Yes / Yes

EPS (ttm)	-1.02
EPS next Y	-0.82
EPS next Q	-0.25
EPS this Y	23.04%
EPS next Y	9.71%
EPS next 5Y	14.13%
EPS past 3/5Y	23.34% 8.80%
Sales past 3/5Y	17.14% 135.14%
EPS Y/Y TTM	17.68%
Sales Y/Y TTM	51.98%
EPS Q/Q	64.26%
Sales Q/Q	112.68%
Earnings	Aug 06 BMO
EPS/Sales Surpr.	59.18% 136.38%

Insider Own	46.74%
Insider Trans	0.00%
Inst Own	47.64%
Inst Trans	1.10%
ROA	-30.06%
ROE	-
ROIC	-
Gross Margin	94.18%
Oper. Margin	-186.38%
Profit Margin	-175.78%
SMA20	-13.40%
SMA50	-51.70%
SMA200	-58.31%
Trades

Shs Outstand	58.71M
Shs Float	31.63M
Short Float	6.81%
Short Ratio	3.15
Short Interest	2.15M
52W High	7.61 -73.59%
52W Low	1.79 12.29%
Volatility	6.47% 12.11%
ATR (14)	0.23
RSI (14)	24.74
Beta	3.18
Rel Volume	0.00
Avg Volume	683.68K
Volume	0

Perf Week	6.35%
Perf Month	-48.06%
Perf Quarter	-58.56%
Perf Half Y	-61.27%
Perf YTD	-62.78%
Perf Year	-49.88%
Perf 3Y	-31.63%
Perf 5Y	-84.17%
Perf 10Y	-
Recom	2.00
Target Price	5.00
Prev Close	2.01
Price	2.01
Change %	0.00%

Date	Action	Analyst	Rating Change	Price Target Change
Oct-13-26	Downgrade	Evercore ISI	Outperform → In-line	$3
Oct-02-26	Downgrade	Wedbush	Outperform → Neutral	$2
Oct-02-26	Downgrade	TD Cowen	Buy → Hold
Oct-02-26	Downgrade	BTIG Research	Buy → Neutral
Feb-17-26	Resumed	Jefferies	Buy	$12
Dec-18-25	Initiated	BTIG Research	Buy	$11
Nov-07-25	Initiated	Guggenheim	Buy	$12
Sep-17-25	Resumed	B. Riley Securities	Buy	$10
Apr-23-25	Initiated	Citizens JMP	Mkt Outperform	$9
Jan-30-25	Initiated	B. Riley Securities	Buy	$10
Sep-03-24	Initiated	Jefferies	Buy	$18
Aug-19-24	Initiated	Evercore ISI	Outperform	$20
Mar-28-23	Initiated	BofA Securities	Buy	$10
Jan-05-23	Initiated	BMO Capital Markets	Outperform	$20
Nov-22-21	Initiated	H.C. Wainwright	Buy	$25
Nov-17-20	Initiated	Wedbush	Outperform	$24
Nov-17-20	Initiated	Morgan Stanley	Overweight	$24
Nov-17-20	Initiated	Goldman	Buy	$27
Nov-17-20	Initiated	Cowen	Outperform

Show Previous Ratings

Oct-02-26 02:12PM	FHTX Stock Extends Sell-Off After Lilly Collaboration Ends Wedbush Slashes Target By 80% (Stocktwits) -30.82%
10:00AM	Foghorn Therapeutics is cutting 40% of its workforce after Eli Lilly ends cancer drug partnership (Quartz)
09:50AM	Foghorn Therapeutics layoffs after Eli Lilly ends cancer deal (Quartz)
Oct-01-26 10:06AM	Foghorn Therapeutics Halts FHD-909 Development After Phase 1 Clinical Data Review (InvestorsHub) -18.21%
09:23AM	FHTX Stock On Track For Record Low Why Did Foghorn And Lilly Pull The Plug On Cancer Drug? (Stocktwits)
07:40AM	Loading…
07:40AM	Foghorn to Slash 40% of Jobs as Lilly Cancer Partnership Falls Apart (Barrons.com)
07:00AM	Foghorn Therapeutics Provides Update on FHD-909 and Strategic Priorities (GlobeNewswire)
Aug-06-26 07:00AM	Foghorn Therapeutics Provides Second Quarter 2026 Financial and Corporate Update (GlobeNewswire) +14.14%
Jun-05-26 07:00AM	Foghorn Therapeutics to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference 2026 (GlobeNewswire)
May-12-26 07:00AM	Foghorn Therapeutics to Participate in Three Upcoming Investor Conferences in May (GlobeNewswire)
May-07-26 07:00AM	Foghorn Therapeutics Provides First Quarter 2026 Financial and Corporate Update (GlobeNewswire) -10.26%
Apr-21-26 04:05PM	Foghorn Therapeutics Presents New Preclinical Data for Selective SMARCA2 Inhibitor FHD-909 and for Selective CBP, EP300 and ARID1B Degrader Programs at the 2026 AACR Annual Meeting (GlobeNewswire)
Apr-09-26 07:00AM	Foghorn Therapeutics to Present New Preclinical Data for Selective SMARCA2 Inhibitor FHD-909 and Selective CBP, EP300 and ARID1B Degrader Programs at the 2026 AACR Annual Meeting (GlobeNewswire)
Mar-11-26 04:09PM	Foghorn Therapeutics Provides Financial Update for 2025 and 2026 Strategic Outlook (GlobeNewswire) -12.92%
Mar-04-26 05:10PM	Verastem (VSTM) Reports Q4 Loss, Beats Revenue Estimates (Zacks)
07:00AM	Loading…
Feb-24-26 07:00AM	Foghorn Therapeutics to Participate in Two Upcoming Investor Conferences (GlobeNewswire)
Feb-23-26 07:00AM	Foghorn Therapeutics Strengthens Financial Leadership with Appointment of Ryan Maynard as Chief Financial Officer (GlobeNewswire)
Feb-13-26 07:03PM	Foghorn Therapeutics CEO Talks Lilly-Partnered SMARCA2 Phase 1 and New Degrader Targets at Conference (MarketBeat) +5.51%
Feb-03-26 07:00AM	Foghorn Therapeutics to Participate in the Guggenheim Emerging Outlook: Biotech Summit (GlobeNewswire)
Jan-14-26 10:52AM	Precision Killers: Why Big Pharma is Betting Billions to Beat a $170B Patent Cliff (PR Newswire) -5.54%
Jan-13-26 04:05PM	Foghorn Therapeutics Announces Closing of $50 Million Registered Direct Financing at a 30% Premium (GlobeNewswire)
Jan-09-26 10:20PM	Foghorn Therapeutics Highlights January Equity Financing, Program Progress and Strategic Objectives for 2026 (GlobeNewswire) +23.64%
Dec-18-25 10:40AM	3 Cancer Stocks to Buy Amid Rapid Advances in Cancer Treatment (Zacks) +7.76%
Dec-11-25 10:17AM	Platform Technologies Drive $211B Surge in Precision Cancer Treatment (PR Newswire)
Nov-25-25 07:00AM	Foghorn Therapeutics to Participate in the 8th Annual Evercore Healthcare Conference (GlobeNewswire)
Nov-19-25 09:55AM	Does Foghorn Therapeutics (FHTX) Have the Potential to Rally 133.27% as Wall Street Analysts Expect? (Zacks)
Nov-05-25 08:15AM	Foghorn Therapeutics Inc. (FHTX) Reports Q3 Loss, Beats Revenue Estimates (Zacks) +13.31%
07:00AM	Foghorn Therapeutics Provides Third Quarter 2025 Financial and Corporate Update (GlobeNewswire)
Nov-03-25 07:30AM	Foghorn Therapeutics to Participate in Three Upcoming Investor Conferences (GlobeNewswire)
Oct-30-25 07:30AM	Foghorn Therapeutics Announces Updates for Selective ARID1B, Selective CBP and Selective EP300 Degrader Programs (GlobeNewswire)
07:00AM	Loading…
Oct-16-25 07:00AM	Foghorn Therapeutics Announces Significant Progress for Selective ARID1B Degrader at the 8th Annual TPD and Induced Proximity Summit (GlobeNewswire)
Sep-10-25 06:42AM	Alnylam (ALNY) Surges 6.0%: Is This an Indication of Further Gains? (Zacks) -5.16%
Sep-01-25 09:55AM	Wall Street Analysts Predict a 130.63% Upside in Foghorn Therapeutics (FHTX): Here's What You Should Know (Zacks)
Aug-27-25 09:40AM	Is Arcutis Biotherapeutics (ARQT) Stock Outpacing Its Medical Peers This Year? (Zacks)
07:00AM	Foghorn Therapeutics to Participate in Three Upcoming Investor Conferences (GlobeNewswire)
Aug-25-25 12:00PM	Foghorn Therapeutics (FHTX) Upgraded to Buy: Here's Why (Zacks) -5.58%
Aug-08-25 09:55AM	Here's Why Foghorn Therapeutics (FHTX) Looks Ripe for Bottom Fishing (Zacks) -8.03%
Aug-05-25 08:10AM	Foghorn Therapeutics Inc. (FHTX) Reports Q2 Loss, Lags Revenue Estimates (Zacks)
07:00AM	Foghorn Therapeutics Provides Second Quarter 2025 Financial and Corporate Update (GlobeNewswire)
Jul-24-25 08:05AM	NovoCure (NVCR) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
May-22-25 07:00AM	Foghorn Therapeutics to Participate in Four Upcoming Investor Conferences (GlobeNewswire)
May-14-25 08:25AM	Foghorn Therapeutics Inc. (FHTX) Reports Q1 Loss, Misses Revenue Estimates (Zacks) -5.08%
07:00AM	Foghorn Therapeutics Provides First Quarter 2025 Financial and Corporate Update (GlobeNewswire)
May-13-25 05:40PM	Inovio Pharmaceuticals (INO) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
May-08-25 05:50PM	Sutro Biopharma, Inc. (STRO) Reports Q1 Loss, Tops Revenue Estimates (Zacks) +13.53% -7.28%
May-06-25 10:12PM	Flagship Pioneering, the National University of Singapore, National University Hospital and the National University Health System Announce Collaboration to Advance Biotech Research & Development (PR Newswire)
May-05-25 07:00AM	Foghorn Therapeutics to Participate in the Citizens Life Sciences Conference (GlobeNewswire) -8.49%
May-01-25 08:15AM	Amicus Therapeutics (FOLD) Q1 Earnings and Revenues Lag Estimates (Zacks)
07:00AM	Foghorn Therapeutics Appoints Neil Gallagher and Stuart Duty to its Board of Directors (GlobeNewswire)
Apr-29-25 08:00AM	Flagship Pioneering Appoints Rahul Kakkar as CEO-Partner and CEO of Quotient Therapeutics (PR Newswire)
Apr-28-25 04:05PM	Foghorn Therapeutics Presents New Preclinical Data on Selective SMARCA2 Inhibitor FHD-909 and Selective CBP and Selective EP300 Degrader Programs and Provides Pipeline Update (GlobeNewswire)
Apr-24-25 06:00AM	Flagship Pioneering Unveils Etiome to Pioneer Preemptive Healthcare (PR Newswire)
Apr-15-25 07:00AM	Foghorn Therapeutics to Host Virtual Investor Event to Review Pipeline Updates in Conjunction with 2025 AACR Annual Meeting (GlobeNewswire)
Apr-01-25 08:00AM	Flagship Pioneering Announces Agreement Between Pioneering Medicines and Pfizer to Discover Potential Novel, Selective Inhibitors for Autoimmune Disease (PR Newswire) -7.53%
Mar-26-25 03:20AM	Foghorn: SMARCA4 Targeting Brings About Treating Up To 10% Of NSCLC Patients (SeekingAlpha)
Mar-25-25 04:35PM	Foghorn Therapeutics Announces New Preclinical Data for Selective SMARCA2 Inhibitor FHD-909 and Selective CBP and EP300 Degrader Programs at 2025 AACR Meeting (GlobeNewswire) -5.92%
08:00AM	Charles River and Valo Health Identify a Potential Therapeutic for Lupus Using Logica, an AI-Powered Drug Discovery Platform (Business Wire)
Mar-20-25 05:19PM	Foghorn Therapeutics scales down ATM stock offering to $100M (SeekingAlpha) -7.21%
Mar-06-25 06:05PM	Foghorn Therapeutics Inc. (FHTX) Reports Q4 Loss, Lags Revenue Estimates (Zacks)
04:05PM	Foghorn Therapeutics Provides Financial Update for 2024 and 2025 Strategic Outlook (GlobeNewswire)
Feb-27-25 10:00AM	Will Foghorn Therapeutics Inc. (FHTX) Report Negative Q4 Earnings? What You Should Know (Zacks) -7.58%
Feb-25-25 07:00AM	Foghorn Therapeutics to Participate in Two Upcoming Investor Conferences (GlobeNewswire)
Feb-11-25 09:24AM	Foghorn Therapeutics (FHTX) Soars 11.4%: Is Further Upside Left in the Stock? (Zacks)
Feb-09-25 06:12AM	Analysts Predict Up to ~450% Surge for These 2 Strong Buy Penny Stocks (TipRanks)
Jan-15-25 09:35AM	Foghorn Therapeutics (FHTX) Loses -23.05% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner (Zacks)
Jan-13-25 07:00AM	Foghorn Therapeutics Highlights Program Progress and Strategic Objectives for 2025 (GlobeNewswire)
Jan-09-25 12:00PM	Foghorn Therapeutics (FHTX) Upgraded to Strong Buy: Here's What You Should Know (Zacks)
Dec-18-24 06:25AM	Foghorn Therapeutics price target lowered to $13 from $20 at H.C. Wainwright (TipRanks) -10.89%
Dec-17-24 07:29AM	Foghorn Therapeutics Advances Precision Oncology Pipeline (TipRanks)
Dec-16-24 07:00AM	Foghorn Therapeutics Provides Update on FHD-286 Clinical Development Program and Strategic Priorities (GlobeNewswire)
Dec-12-24 09:35AM	After Plunging -30.17% in 4 Weeks, Here's Why the Trend Might Reverse for Foghorn Therapeutics (FHTX) (Zacks) -6.47%
Nov-29-24 12:00PM	Foghorn Therapeutics (FHTX) Upgraded to Buy: Here's Why (Zacks)
Nov-25-24 09:55AM	Wall Street Analysts See a 104.08% Upside in Foghorn Therapeutics (FHTX): Can the Stock Really Move This High? (Zacks)
Nov-20-24 08:00AM	Flagship Pioneering Appoints Angela Hwang as CEO-Partner and Chief Executive Officer of Metaphore Biotechnologies (PR Newswire)
06:30AM	Flagship Pioneering Announces Two New Agreements with Ampersand Biomedicines and Montai Therapeutics Under its Strategic Partnership with Pfizer (PR Newswire)
Nov-13-24 08:00AM	Flagship Pioneering Appoints Craig Williams as CEO-Partner and Chief Executive Officer of Apriori Bio (PR Newswire)
08:00AM	Brian M. Alexander Joins Valo Health as Chief Executive Officer and Flagship Pioneering as CEO-Partner (PR Newswire)
Nov-12-24 07:54AM	Foghorn Therapeutics to Participate in Three Upcoming Investor Conferences (GlobeNewswire)
Nov-04-24 05:25PM	Foghorn Therapeutics Inc. (FHTX) Reports Q3 Loss, Misses Revenue Estimates (Zacks) +8.50%
04:05PM	Foghorn Therapeutics Provides Third Quarter 2024 Financial and Corporate Update (GlobeNewswire)
Oct-23-24 08:00AM	Flagship Pioneering Announces Appointment of Junaid Bajwa as Senior Partner, Head of United Kingdom, and Science Partner for Pioneering Intelligence (PR Newswire)
Oct-11-24 07:47AM	Foghorn Therapeutics Unveils Clinical Pipeline Progress (TipRanks) +8.07%
Oct-10-24 07:00AM	Foghorn Therapeutics Announces First Patient Dosed with First-in-Class Oral SMARCA2 Selective Inhibitor FHD-909 in a Phase 1 Trial for SMARCA4 Mutated Solid Tumors (GlobeNewswire)
Oct-09-24 07:00AM	Flagship Pioneering Announces Appointment of Paul Parker as Managing Partner, Leading Capital Solutions (PR Newswire)
Oct-03-24 08:00AM	Invaio Sciences Appoints Andr Andonian as Chairman of the Board of Directors (PR Newswire) -10.20%
Oct-01-24 07:00AM	Foghorn Therapeutics to Participate in the BMO Oncology Summit (GlobeNewswire) -6.87%
Sep-26-24 06:00AM	Flagship Pioneering Unveils Mirai Bio to Provide Fully Integrated End-to-End Genetic Medicine Development Capabilities for the Biotech Industry (PR Newswire) +5.79%
Sep-24-24 09:15AM	Optimism Grows in the Fight Against Cancer as Breakthroughs and Funding Increase (PR Newswire)
Sep-16-24 04:12AM	Strength Seen in Foghorn Therapeutics (FHTX): Can Its 9.5% Jump Turn into More Strength? (Zacks)
Sep-11-24 07:02PM	Insider Sale: Chief Scientific Officer Steven Bellon Sells 20,000 Shares of Foghorn ... (GuruFocus.com)
Sep-03-24 07:00AM	Foghorn Therapeutics Strengthens Leadership Team with Appointment of Anna Rivkin, Ph.D. as Chief Business Officer (GlobeNewswire) -5.19%
Sep-02-24 09:55AM	Wall Street Analysts Think Foghorn Therapeutics (FHTX) Could Surge 81.16%: Read This Before Placing a Bet (Zacks)
Aug-28-24 07:00AM	Foghorn Therapeutics to Participate in Two Upcoming Investor Conferences in September (GlobeNewswire)
06:30AM	Flagship Pioneering and Quotient Therapeutics Announce Agreement to Identify Potential Novel Targets for the Treatment of Cardiovascular and Renal Diseases under Strategic Partnership with Pfizer (PR Newswire)
Aug-16-24 09:55AM	Wall Street Analysts Believe Foghorn Therapeutics (FHTX) Could Rally 121.77%: Here's is How to Trade (Zacks)
Aug-08-24 08:10AM	Foghorn Therapeutics Inc. (FHTX) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
07:00AM	Foghorn Therapeutics Provides Second Quarter 2024 Financial and Corporate Update (GlobeNewswire)
Aug-06-24 06:30AM	Flagship Pioneering Announces Appointment of Raj Panjabi as Senior Partner (PR Newswire)
Jul-29-24 07:00AM	GSK and Flagship Pioneering partner to discover novel medicines and vaccines (PR Newswire)
Jul-25-24 08:00AM	Analog Devices and Flagship Pioneering Announce Strategic Partnership to Accelerate the Development of a Fully Digitized Biological World (PR Newswire)

Show Previous News

Foghorn Therapeutics, Inc. operates as a development stage biopharmaceutical company. It is discovering and developing a novel class of precision medicine therapeutics targeting the chromatin regulatory system in oncology. Through its scalable Gene Traffic Control product platform, the firm is systematically interrogating and drugging the chromatin regulatory system. The company was founded by Cigall Kadoch, Gerald W. Crabtree and Douglas G. Cole in October 2015 and is headquartered in Watertown, MA.

Founder & Independent Chairman of the BoardDr. Douglas G. Cole M.D.

PresidentMr. Adrian H. B. Gottschalk

Chief Scientific OfficerDr. Steven F. Bellon Ph.D.

Chief Medical OfficerDr. Alfonso Quintas Cardama M.D.

Founder & Member of Scientific Advisory BoardDr. Gerald R. Crabtree M.d.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

Foghorn Therapeutics Inc

Upgrade your Finviz experience